Tin tức & Cập nhật
Xem bài viết Dược
Xem
Sacituzumab govitecan makes case as third-line therapy in mTNBC
Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.
Erdafitinib prevents recurrence in high-risk NMIBC
Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.
Amivantamab plus chemo improves survival in advanced NSCLC
Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.
Shorter antibiotic dosing for pneumonia holds up against usual care in Asians
In the treatment of Asian patients with ventilator-associated pneumonia (VAP), shortened antibiotic treatment duration guided by clinical response compares favourably with longer treatment durations used in usual care in terms of 60-day mortality and pneumonia recurrence, as shown in the open-label REGARD-VAP trial.
Internal mammary nodes irradiation prolongs survival in breast cancer
The addition of internal mammary nodal irradiation (IMNI) in the treatment of breast cancer leads to better overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and lower breast cancer mortality (BCM), reveals a study. In addition, patients with pN+ and medial/central tumour location achieved the best OS from IMNI.
